Drug Database · Clinicians

Bortezomib

Brands (41) Borteget, Ambizom, Mibor…Show all

Proteasome Inhibitor (Proteasome Inhibitors) US FDA class
Antineoplastic agent (proteasome inhibitor); Antineoplastic (proteasome inhibitor) PH FDA category

Rx · Prescription drug52 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 1521d321-e724-4ffc-adad-34bf4f44fac7, version date August 28, 2025 (VELCADE · Takeda Pharmaceuticals America, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • treatment of adult patients with multiple myeloma
  • treatment of adult patients with mantle cell lymphoma
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma (1.1) treatment of adult patients with mantle cell lymphoma (1.2) 1.1 Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma.

Contraindications

4 CONTRAINDICATIONS VELCADE is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [see Adverse Reactions (6.1)]. VELCADE is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of VELCADE. Patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions. (4) Contraindicated for intrathecal administration. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration. Exercise caution when calculating the volume to be administered. (2.1, 2.10)
  • The recommended starting dose of VELCADE is 1.3 mg/m 2 administered either as a 3 to 5 second bolus intravenous injection or subcutaneous injection. (2.2, 2.4, 2.6)
  • Retreatment for Multiple Myeloma: May retreat starting at the last tolerated dose. (2.6)
  • Hepatic Impairment: Use a lower starting dose for patients with moderate or severe hepatic impairment. (2.8)
  • Dose must be individualized to prevent overdose. (2.10)
2.1 Important Dosing Guidelines

2.1 Important Dosing Guidelines VELCADE is for intravenous or subcutaneous use only. Do not administer VELCADE by any other route. Because each route of administration has a different reconstituted concentration, use caution when calculating the volume to be administered. The recommended starting dose of VELCADE is 1.3 mg/m 2.

VELCADE is administered intravenously at a concentration of 1 mg/mL, or subcutaneously at a concentration of 2.5 mg/mL [see Dosage and Administration (2.10)]. VELCADE retreatment may be considered for patients with multiple myeloma who had previously responded to treatment with VELCADE and who have relapsed at least six months after completing prior VELCADE treatment.

Treatment may be started at the last tolerated dose [see Dosage and Administration (2.6)]. When administered intravenously, administer VELCADE as a 3 to 5 second bolus intravenous injection.

2.2 Dosage in Previously Untreated Multiple Myeloma

2.2 Dosage in Previously Untreated Multiple Myeloma VELCADE is administered in combination with oral melphalan and oral prednisone for 9, six week treatment cycles as shown in Table 1. In Cycles 1 to 4, VELCADE is administered twice weekly (Days 1, 4, 8, 11, 22, 25, 29 and 32). In Cycles 5 to 9, VELCADE is administered once weekly (Days 1, 8, 22 and 29).

At least 72 hours should elapse between consecutive doses of VELCADE. Table 1: Dosage Regimen for Patients with Previously Untreated Multiple Myeloma Twice Weekly VELCADE (Cycles 1 to 4) Week 1 2 3 4 5 6 VELCADE (1.3 mg/m 2) Day 1 -- -- Day 4 Day 8 Day 11 rest period Day 22 Day 25 Day 29 Day 32 rest period Melphalan (9 mg/m 2) Prednisone (60 mg/m 2) Day 1 Day 2 Day 3 Day 4 -- -- rest period -- -- -- -- rest period Once Weekly VELCADE (Cycles 5 to 9 when used in combination with Melphalan and Prednisone) Week 1 2 3 4 5 6 VELCADE (1.3 mg/m 2) Day 1 -- -- Day 8 rest period Day 22 Day 29 rest period Melphalan (9 mg/m 2) Prednisone (60 mg/m 2) Day 1 Day 2 Day 3 Day 4 -- -- rest period -- -- -- -- rest period

2.3 Dose Modification Guidelines

2.3 Dose Modification Guidelines for VELCADE When Given in Combination with Melphalan and Prednisone Prior to initiating any cycle of therapy with VELCADE in combination with melphalan and prednisone: Platelet count should be at least 70 × 10 9 /L and the absolute neutrophil count (ANC) should be at least 1 × 10 9 /L Nonhematological toxicities should have resolved to Grade 1 or baseline Table 2: Dose Modifications During Cycles of Combination VELCADE, Melphalan and Prednisone Therapy Toxicity Dose Modification or Delay Hematological toxicity during a cycle: If prolonged Grade 4 neutropenia or thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle Consider reduction of the melphalan dose by 25% in the next cycle If platelet count is not above 30 × 10 9 /L or ANC is not above 0.75 × 10 9 /L on a VELCADE dosing day (other than Day 1) Withhold VELCADE dose If several VELCADE doses in consecutive cycles are withheld due to toxicity Reduce VELCADE dose by one dose level (from 1.3 mg/m 2 to 1 mg/m 2, or from 1 mg/m 2 to 0.7 mg/m 2) Grade 3 or higher nonhematological toxicities Withhold VELCADE therapy until symptoms of toxicity have resolved to Grade 1 or baseline. Then, VELCADE may be reinitiated with one dose level reduction (from 1.3 mg/m 2 to 1 mg/m 2, or from 1 mg/m 2 to 0.7 mg/m 2).

For VELCADE-related neuropathic pain and/or peripheral neuropathy, hold or modify VELCADE as outlined in Table 5. For information concerning melphalan and prednisone, see manufacturer's prescribing information. Dose modifications guidelines for peripheral neuropathy are provided [see Dosage and Administration (2.7)].

2.4 Dosage in Previously Untreated Mantle Cell Lymphoma

2.4 Dosage in Previously Untreated Mantle Cell Lymphoma VELCADE (1.3 mg/m 2) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (VcR-CAP) for 6, three week treatment cycles as shown in Table 3. VELCADE is administered first followed by rituximab. VELCADE is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a ten day rest period on Days 12 to 21.

For patients with a response first documented at Cycle 6, two additional VcR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of VELCADE. Table 3: Dosage Regimen for Patients with Previously Untreated Mantle Cell Lymphoma Twice Weekly VELCADE (6, Three Week Cycles) Dosing may continue for two more cycles (for a total of eight cycles) if response is first seen at Cycle 6.

Week 1 2 3 VELCADE (1.3 mg/m 2) Day 1 -- -- Day 4 -- Day 8 Day 11 rest period Rituximab (375 mg/m 2) Cyclophosphamide (750 mg/m 2) Doxorubicin (50 mg/m 2) Day 1 -- -- -- -- rest period Prednisone (100 mg/m 2) Day 1 Day 2 Day 3 Day 4 Day 5 -- -- rest period

2.5 Dose Modification Guidelines

2.5 Dose Modification Guidelines for VELCADE When Given in Combination with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone Prior to the first day of each cycle (other than Cycle 1): Platelet count should be at least 100 × 10 9 /L and absolute neutrophil count (ANC) should be at least 1.5 × 10 9 /L Hemoglobin should be at least 8 g/dL (at least 4.96 mmol/L) Nonhematologic toxicity should have recovered to Grade 1 or baseline Interrupt VELCADE treatment at the onset of any Grade 3 hematologic or nonhematological toxicities, excluding neuropathy [see Table 5, Warnings and Precautions (5)]. For dose adjustments, see Table 4 below.

Table 4: Dose Modifications on Days 4, 8, and 11 During Cycles of Combination VELCADE, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone Therapy Toxicity Dose Modification or Delay Hematological Toxicity Grade 3 or higher neutropenia, or a platelet count not at or above 25 × 10 9 /L Withhold VELCADE therapy for up to 2 weeks until the patient has an ANC at or above 0.75 × 10 9 /L and a platelet count at or above 25 × 10 9 /L. If, after VELCADE has been withheld, the toxicity does not resolve, discontinue VELCADE.

If toxicity resolves such that the patient has an ANC at or above 0.75 × 10 9 /L and a platelet count at or above 25 × 10 9 /L, VELCADE dose should be reduced by 1 dose level (from 1.3 mg/m 2 to 1 mg/m 2, or from 1 mg/m 2 to 0.7 mg/m 2). Grade 3 or higher nonhematological toxicities Withhold VELCADE therapy until symptoms of the toxicity have resolved to Grade 2 or better.

Then, VELCADE may be reinitiated with one dose level reduction (from 1.3 mg/m 2 to 1 mg/m 2, or from 1 mg/m 2 to 0.7 mg/m 2). For VELCADE-related neuropathic pain and/or peripheral neuropathy, hold or modify VELCADE as outlined in Table 5. For information concerning rituximab, cyclophosphamide, doxorubicin and prednisone, see manufacturer's prescribing information.

2.6 Dosage and Dose Modifications for Relapsed Multiple Myeloma

2.6 Dosage and Dose Modifications for Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma VELCADE (1.3 mg/m 2 /dose) is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a ten day rest period (Days 12 to 21). For extended therapy of more than eight cycles, VELCADE may be administered on the standard schedule or, for relapsed multiple myeloma, on a maintenance schedule of once weekly for four weeks (Days 1, 8, 15, and 22) followed by a 13 day rest period (Days 23 to 35) [see Clinical Studies (14)].

At least 72 hours should elapse between consecutive doses of VELCADE. Patients with multiple myeloma who have previously responded to treatment with VELCADE (either alone or in combination) and who have relapsed at least six months after their prior VELCADE therapy may be started on VELCADE at the last tolerated dose. Retreated patients are administered VELCADE twice weekly (Days 1, 4, 8, and 11) every three weeks for a maximum of eight cycles.

At least 72 hours should elapse between consecutive doses of VELCADE. VELCADE may be administered either as a single agent or in combination with dexamethasone [see Clinical Studies (14.1)]. VELCADE therapy should be withheld at the onset of any Grade 3 nonhematological or Grade 4 hematological toxicities excluding neuropathy as discussed below [see Warnings and Precautions (5)].

Once the symptoms of the toxicity have resolved, VELCADE therapy may be reinitiated at a 25% reduced dose (1.3 mg/m 2 /dose reduced to 1 mg/m 2 /dose; 1 mg/m 2 /dose reduced to 0.7 mg/m 2 /dose). For dose modifications guidelines for peripheral neuropathy, see section 2.7.

2.7 Dose Modifications for Peripheral Neuropathy Starting

2.7 Dose Modifications for Peripheral Neuropathy Starting VELCADE subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy. Patients with pre-existing severe neuropathy should be treated with VELCADE only after careful risk-benefit assessment. Patients experiencing new or worsening peripheral neuropathy during VELCADE therapy may require a decrease in the dose and/or a less dose-intense schedule.

For dose or schedule modification guidelines for patients who experience VELCADE-related neuropathic pain and/or peripheral neuropathy, see Table 5. Table 5: Recommended Dose Modification for VELCADE-Related Neuropathic Pain and/or Peripheral Sensory or Motor Neuropathy Severity of Peripheral Neuropathy Signs and Symptoms Grading based on NCI Common Terminology Criteria CTCAE v4.0 Modification of Dose and Regimen Grade 1 (asymptomatic; loss of deep tendon reflexes or paresthesia) without pain or loss of function No action Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental Activities of Daily Living (ADL) Instrumental ADL: refers to preparing meals, shopping for groceries or clothes, using telephone, managing money, etc.) Reduce VELCADE to 1 mg/m 2 Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADL Self care ADL: refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden) Withhold VELCADE therapy until toxicity resolves.

When toxicity resolves reinitiate with a reduced dose of VELCADE at 0.7 mg/m 2 once per week. Grade 4 (life-threatening consequences; urgent intervention indicated) Discontinue VELCADE

2.8 Dosage in Patients with Hepatic Impairment

2.8 Dosage in Patients with Hepatic Impairment Do not adjust the starting dose for patients with mild hepatic impairment. Start patients with moderate or severe hepatic impairment at a reduced dose of 0.7 mg/m 2 per injection during the first cycle, and consider subsequent dose escalation to 1 mg/m 2 or further dose reduction to 0.5 mg/m 2 based on patient tolerance (see Table 6) [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].

Table 6: Recommended Starting Dose Modification for VELCADE in Patients with Hepatic Impairment Bilirubin Level SGOT (AST) Levels Modification of Starting Dose Abbreviations: SGOT = serum glutamic oxaloacetic transaminase; AST = aspartate aminotransferase; ULN = upper limit of the normal range. Mild Less than or equal to 1× ULN More than ULN None More than 1× to 1.5× ULN Any None Moderate More than 1.5× to 3× ULN Any Reduce VELCADE to 0.7 mg/m 2 in the first cycle.

Consider dose escalation to 1 mg/m 2 or further dose reduction to 0.5 mg/m 2 in subsequent cycles based on patient tolerability. Severe More than 3× ULN Any

2.9 Administration Precautions

2.9 Administration Precautions The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required. Caution should be used in calculating the dose to prevent overdose [see Dosage and Administration (2.10)]. When administered subcutaneously, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated.

If local injection site reactions occur following VELCADE administration subcutaneously, a less concentrated VELCADE solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously [see Dosage and Administration (2.10)]. Alternatively, consider use of the intravenous route of administration [see Dosage and Administration (2.10)].

VELCADE is a hazardous drug. Follow applicable special handling and disposal procedures. 1

2.10 Reconstitution/Preparation for Intravenous and Subcutaneous Administration

2.10 Reconstitution/Preparation for Intravenous and Subcutaneous Administration Use proper aseptic technique. Reconstitute only with 0.9% sodium chloride. The reconstituted product should be a clear and colorless solution. Different volumes of 0.9% sodium chloride are used to reconstitute the product for the different routes of administration.

The reconstituted concentration of bortezomib for subcutaneous administration (2.5 mg/mL) is greater than the reconstituted concentration of bortezomib for intravenous administration (1 mg/mL). Because each route of administration has a different reconstituted concentration, use caution when calculating the volume to be administered [see Dosage and Administration (2.9)].

For each 3.5 mg single-dose vial of bortezomib, reconstitute with the following volume of 0.9% sodium chloride based on route of administration (Table 7): Table 7: Reconstitution Volumes and Final Concentration for Intravenous and Subcutaneous Administration Route of Administration Bortezomib (mg/vial) Diluent (0.9% Sodium Chloride) Final Bortezomib Concentration (mg/mL) Intravenous 3.5 mg 3.5 mL 1 mg/mL Subcutaneous 3.5 mg 1.4 mL 2.5 mg/mL Dose must be individualized to prevent overdosage. After determining patient body surface area (BSA) in square meters, use the following equations to calculate the total volume (mL) of reconstituted VELCADE to be administered: Intravenous Administration [1 mg/mL concentration] VELCADE dose (mg/m 2) × patient BSA (m 2) =Total VELCADE volume (mL) to be administered 1 mg/mL Subcutaneous Administration [2.5 mg/mL concentration] VELCADE dose (mg/m 2) × patient BSA (m 2) =Total VELCADE volume (mL) to be administered 2.5 mg/mL Stickers that indicate the route of administration are provided with each VELCADE vial.

These stickers should be placed directly on the syringe of VELCADE once VELCADE is prepared to help alert practitioners of the correct route of administration for VELCADE. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

If any discoloration or particulate matter is observed, the reconstituted product should not be used. Stability Unopened vials of VELCADE are stable until the date indicated on the package when stored in the original package protected from light. VELCADE contains no antimicrobial preservative. Administer reconstituted VELCADE within eight hours of preparation.

When reconstituted as directed, VELCADE may be stored at 25°C (77°F). The reconstituted material may be stored in the original vial and/or the syringe prior to administration. The product may be stored for up to eight hours in a syringe; however, total storage time for the reconstituted material must not exceed eight hours when exposed to normal indoor lighting.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment No starting dosage adjustment of VELCADE is recommended for patients with renal impairment. In patients requiring dialysis, VELCADE should be administered after the dialysis procedure [see Clinical Pharmacology (12.3)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment No starting dosage adjustment of VELCADE is recommended for patients with mild hepatic impairment (total bilirubin ≤1× ULN and AST >ULN, or total bilirubin >1 to 1.5× ULN and any AST). The exposure of bortezomib is increased in patients with moderate (total bilirubin ≥1.5 to 3× ULN and any AST) and severe (total bilirubin >3× ULN and any AST) hepatic impairment. Reduce the starting dose in patients with moderate or severe hepatic impairment [see Dosage and Administration (2.8), Clinical Pharmacology (12.3)].

2.8 Dosage in Patients with Hepatic Impairment Do not adjust the starting dose for patients with mild hepatic impairment. Start patients with moderate or severe hepatic impairment at a reduced dose of 0.7 mg/m 2 per injection during the first cycle, and consider subsequent dose escalation to 1 mg/m 2 or further dose reduction to 0.5 mg/m 2 based on patient tolerance (see Table 6) [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].

Table 6: Recommended Starting Dose Modification for VELCADE in Patients with Hepatic Impairment Bilirubin Level SGOT (AST) Levels Modification of Starting Dose Abbreviations: SGOT = serum glutamic oxaloacetic transaminase; AST = aspartate aminotransferase; ULN = upper limit of the normal range. Mild Less than or equal to 1× ULN More than ULN None More than 1× to 1.5× ULN Any None Moderate More than 1.5× to 3× ULN Any Reduce VELCADE to 0.7 mg/m 2 in the first cycle.

Consider dose escalation to 1 mg/m 2 or further dose reduction to 0.5 mg/m 2 in subsequent cycles based on patient tolerability. Severe More than 3× ULN Any

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness have not been established in pediatric patients. The activity and safety of VELCADE in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies (pre-B cell ALL 77%, 16% with T-cell ALL, and 7% T-cell lymphoblastic lymphoma (LL)), all of whom relapsed within 36 months of initial diagnosis in a single-arm multicenter, nonrandomized cooperative group trial.

An effective reinduction multiagent chemotherapy regimen was administered in three blocks. Block 1 included vincristine, prednisone, doxorubicin and pegaspargase; Block 2 included cyclophosphamide, etoposide and methotrexate; Block 3 included high-dose cytosine arabinoside and asparaginase. VELCADE was administered at a dose of 1.3 mg/m 2 as a bolus intravenous injection on Days 1, 4, 8, and 11 of Block 1 and Days 1, 4, and 8 of Block 2.

There were 140 patients with ALL or LL enrolled and evaluated for safety. The median age was ten years (range: 1 to 26), 57% were male, 70% were white, 14% were black, 4% were Asian, 2% were American Indian/Alaska Native, 1% were Pacific Islander. The activity was evaluated in a prespecified subset of the first 60 evaluable patients enrolled on the study with pre-B ALL ≤21 years and relapsed <36 months from diagnosis.

The complete remission (CR) rate at day 36 was compared to that in a historical control set of patients who had received the identical backbone therapy without VELCADE. There was no evidence that the addition of VELCADE had any impact on the CR rate. No new safety concerns were observed when VELCADE was added to a chemotherapy backbone regimen as compared with a historical control group in which the backbone regimen was given without VELCADE.

The BSA-normalized clearance of bortezomib in pediatric patients was similar to that observed in adults.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 669 patients enrolled in the relapsed multiple myeloma study, 245 (37%) were 65 years of age or older: 125 (38%) on the VELCADE arm and 120 (36%) on the dexamethasone arm. Median time to progression and median duration of response for patients ≥65 were longer on VELCADE compared to dexamethasone [5.5 mo vs 4.3 mo, and 8.0 mo vs 4.9 mo, respectively].

On the VELCADE arm, 40% (n=46) of evaluable patients aged ≥65 experienced response (CR + PR) vs 18% (n=21) on the dexamethasone arm. The incidence of Grade 3 and 4 events was 64%, 78% and 75% for VELCADE patients ≤50, 51 to 64 and ≥65 years old, respectively [see Adverse Reactions (6.1), Clinical Studies (14.1)]. No overall differences in safety or effectiveness were observed between patients ≥age 65 and younger patients receiving VELCADE; but greater sensitivity of some older individuals cannot be ruled out.

Administration

2.9 Administration Precautions The drug quantity contained in one vial (3.5 mg) may exceed the usual dose required. Caution should be used in calculating the dose to prevent overdose [see Dosage and Administration (2.10) ] . When administered subcutaneously, sites for each injection (thigh or abdomen) should be rotated. New injections should be given at least one inch from an old site and never into areas where the site is tender, bruised, erythematous, or indurated. If local injection site reactions occur following VELCADE administration subcutaneously, a less concentrated VELCADE solution (1 mg/mL instead of 2.5 mg/mL) may be administered subcutaneously [see Dosage and Administration (2.10) ] . Alternatively, consider use of the intravenous route of administration [see Dosage and Administration (2.10) ] . VELCADE is a hazardous drug. Follow applicable special handling and disposal procedures. 1

2.10 Reconstitution/Preparation for Intravenous and Subcutaneous Administration Use proper aseptic technique. Reconstitute only with 0.9% sodium chloride . The reconstituted product should be a clear and colorless solution. Different volumes of 0.9% sodium chloride are used to reconstitute the product for the different routes of administration. The reconstituted concentration of bortezomib for subcutaneous administration (2.5 mg/mL) is greater than the reconstituted concentration of bortezomib for intravenous administration (1 mg/mL). Because each route of administration has a different reconstituted concentration, use caution when calculating the volume to be administered [see Dosage and Administration (2.9) ] . For each 3.5 mg single-dose vial of bortezomib, reconstitute with the following volume of 0.9% sodium chloride based on route of administration (Table 7) : Table 7: Reconstitution Volumes and Final Concentration for Intravenous and Subcutaneous Administration Route of Administration Bortezomib (mg/vial) Diluent (0.9% Sodium Chloride) Final Bortezomib Concentration (mg/mL) Intravenous 3.5 mg 3.5 mL 1 mg/mL Subcutaneous 3.5 mg 1.4 mL 2.5 mg/mL Dose must be individualized to prevent overdosage. After determining patient body surface area (BSA) in square meters, use the following equations to calculate the total volume (mL) of reconstituted VELCADE to be administered: Intravenous Administration [1 mg/mL concentration] VELCADE dose (mg/m 2 ) × patient BSA (m 2 ) =Total VELCADE volume (mL) to be administered 1 mg/mL Subcutaneous Administration [2.5 mg/mL concentration] VELCADE dose (mg/m 2 ) × patient BSA (m 2 ) =Total VELCADE volume (mL) to be administered 2.5 mg/mL Stickers that indicate the route of administration are provided with each VELCADE vial. These stickers should be placed directly on the syringe of VELCADE once VELCADE is prepared to help alert practitioners of the correct route of administration for VELCADE. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. If any discoloration or particulate matter is observed, the reconstituted product should not be used. Stability Unopened vials of VELCADE are stable until the date indicated on the package when stored in the original package protected from light. VELCADE contains no antimicrobial preservative. Administer reconstituted VELCADE within eight hours of preparation. When reconstituted as directed, VELCADE may be stored at 25°C (77°F). The reconstituted material may be stored in the original vial and/or the syringe prior to administration. The product may be stored for up to eight hours in a syringe; however, total storage time for the reconstituted material must not exceed eight hours when exposed to normal indoor lighting.

US FDA label

Dosage forms

Philippines

  • Lyophilized powder for injection: 1 mg, 2 mg, 2.5 mg, 3.5 mg, 3.5 mg/Vial
  • Lyophilized powder for solution for injection: 1 mg, 3.5 mg
  • Powder for solution for injection: 2 mg, 3.5 mg
  • Lyophilized powder for i.v. infusion: 3.5 mg/vial
  • Lyophilized powder for solution for injection.: 3.5 mg

Registered products in the Philippines

52 products registered with the Food and Drug Administration (FDA) Philippines list Bortezomib as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products52
Philippine FDA-registered products for Bortezomib
Package insert
AmbizomBortezomib
1 mg Lyophilized Powder for Injection (IV/SC)7 mL Type I clear borosilicate glass vial with a Teflon coated chlorobutyl rubber stopper and aluminum flip- off cap with polypropylene disk (Box of 1's)
RxVAT-exempt
Sichuan Huiyi Pharmaceutical Co. Ltd.China
AMB HK Enterprises Inc.
DRP-17427
Jan 19, 2031
AmbizomBortezomib
3.5 mg Lyophilized Powder for Injection (IV/SC)10 mL Type I clear borosilicate glass vial with a Teflon coated chlorobutyl rubber stopper and aluminum flip-off cap with polypropylene disk (Box of 1's)
RxVAT-exempt
Sichuan Huiyi Pharmaceutical Co. Ltd.China
AMB HK Enterprises Inc.
DRP-17428
Jan 19, 2031
BetozomibBortezomib
3.5 mg Lyophilized Powder for Injection (IV)Type I Flint Transparent Tubular Glass Vial x 15 mL Box of 1’s
RxVAT-exempt
Getwell PharmaceuticalsIndia
AMBICARE PHARMACEUTICALS INC.Importer: Ambica International Corporation
DRP-5513-01
Sep 15, 2029
BezomBortezomib
3.5 mg Powder for Solution for Injection (SC/IV)Type I Tubular clear glass vial x 10 mL with gray bromobutyl rubber stopper and flip-off seal (Box of 1's)
RxVAT-exempt
Hetero Labs LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-7704
Aug 19, 2028
BiomibBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (I.V./S.C.)8 mL clear, colorless glass vial with bromobutyl rubber stopper and aluminum flip-off cap with white-colored polypropylene disk (Box of 1's)
RxVAT-exempt
PharmIdea SIALatvia
UNILAB, Inc.Trader: Logenex Pharm GmbH
DRP-9531
Mar 3, 2031
BoramirBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (IV/SC)USP Type-I glass vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int'l Pvt. Ltd.
DRP-7279-03
Jul 28, 2027
Borte Trust 3.5Bortezomib
3.5mg Lyophilized Powder for Injection (IV/SC)10 mL Type I Clear Tubular Borosilicate Glass Vial with Bromobutyl Rubber Stopper and Light Blue Aluminum Seal and Flip-Off Cap x l's (Box of 1's)
RxVAT-exempt
Panacea Biotec Ltd.India
Medinova Pharmaceutical, Inc.
DRP-12665
Sep 21, 2027
BortebinBortezomib
3.5 mg Lyophilized Powder for Injection (S.C./1.V.)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper (Lyo-gloo) and Aluminum Seal (Lacquered) with Red PP Disk (Box of l's)
RxVAT-exempt
Eugia Pharma Specialties LimitedIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-10645
Nov 22, 2026
BORTEGETBortezomib
3.5 mg Lyophilized Powder for Injection (IV)Type I Flint Transparent Tubular Glass Vial x 15 mL Box of 1’s
RxVAT-exempt
Getwell PharmaceuticalsIndia
GETMEDS PHILIPPINES INC.Importer: Ambica International Corporation
DRP-5513-04
Sep 15, 2029
BortegetBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (I.V./S.C.)USP Type I clear colorless glass vial with 20mm grey bromobutyl rubber stopper and 20 mm aluminum seal with plastic flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Getmeds Philippines Inc.Importer: 2MG Incorporated
DRP-15764-01
Sep 12, 2029
BortegetBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (IV/SC)USP Type-I glass vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Getmeds Philippines Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int'l Pvt. Ltd.
DRP-7279-02
Jul 28, 2027
BorteMedBortezomib
3.5 mg Lyophilized Powder for Injection (I.V.)
RxVAT-exempt
Venus Remedies, LimitedIndia
2MG Incorporated
DRP17608
Feb 19, 2031
BortesumBortezomib
3.5 mg/ Vial Lyophilized Powder for Injection (IV/SC)Colorless Tubular Glass Vial with Grey Rubber Stopper Sealed with Light Green F/O on Both Sides with Clear Lacquer Coated Aluminum Seal x 10 mL Box of 1's
RxVAT-exempt
Sun Pharmaceutical Industries Ltd.India
Sun Pharma Philippines, Inc.
DRP-8735
Oct 3, 2027
BortetherBortezomib
3.5 mg Lyophilized Powder For Injection (I.V)Type I clear glass vial (Box of 1's)
RxVAT-exempt
Therdose Pharma Pvt. Ltd.India
MedEthix Incorporated
DRP-5230
Jul 26, 2028
BortewellBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (IV/SC)8 mL-capacity USP Type I clear and colorless glass vial sealed with grey 20-D2 lyophilization bromobutyl rubber stopper for injection and aluminum seal with blue plastic flip-off cap (Box of 1's)
RxVAT-exempt
Jiangsu Hanson Pharmaceutical Co. Ltd.China
Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc.
DRP-14931
Feb 14, 2029
BORTOZEBBortezomib
3.5 mg Lyophilized Powder for Injection (IV)Type I Flint Transparent Tubular Glass Vial x 15 mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-5513-03
Sep 15, 2029
BortracBortezomib
3.5 mg Lyophilized Powder for Injection (I.V./S.C)USP Type I Glass vial sealed with 13 mm Grey bromo butyl slotted rubber stopper and 13 mm blue flip-off seal (Box of 1's)
RxVAT-exempt
Shilpa Medicare LimitedIndia
Glenmark Philippines, Inc.
DRP-8910
Jun 23, 2031
BorvexBortezomib
3.5 mg Powder for Solution for Injection (IV/SC)In a box of 1-10 mL USP Type I Clear Glass Vial
RxVAT-exempt
Admac LifesciencesIndia
VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd
DR-XY44719
Aug 4, 2030
DotrexBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (IV/SC)USP Type-I glass vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals Int'l Pvt. Ltd.
DRP-7279
Jul 28, 2032
Dotrex 2Bortezomib
2 mg Powder for Solution for Injection (IV/SC)USP Type -I glass vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Ambica International CorporationTrader: BDR Pharmaceuticals Int'l Pvt., Ltd
DRP-7643
Jan 26, 2028
Emibortezo-3.5Bortezomib
3.5 mg Lyophilized Powder for Injection (IV/SC)10 mL-capacity USP Type I clear glass vial sealed with 20 mm slotted bromobutyl rubber stopper and 20 mm green flip off seal (Box of 1 's)
RxVAT-exempt
Admac LifesciencesIndia
Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp.
DRP-14495-01
Sep 13, 2028
FonkozomibBortezomib
3.5 mg Lyophilized Powder for Injection (IV)Type I Clear Fiolax Tubular Glass Vial with Grey Bromobutyl Rubber Stopper Sealed with Aluminum Cap and White Flip-Off Seal (Box of 1's)
RxVAT-exempt
PT FONKO INTERNATIONAL PHARMACEUTICALSIndonesia
Glorious Dexa Mandaya, Inc.Importer: Glorious Dexa Mandaya, Inc
DRP-11312
Sep 16, 2029
KemizobBortezomib
3.5 mg Lyophilized Powder For Injection (S.C./I.V.)Eu.Ph. Type I Clear Glass Vial Stoppered With 20 Mm Grey Butyl Rubber Stopper, Sealed With Aluminum Seal And Red Flip-Off Cap (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
Genace Pharma DistributorImporter: Aglobal Care, Inc.
DRP-9173
Sep 25, 2030
LymphiomibBortezomib
3.5mg Lyophilized Powder For Solution For Injection10 mL-capacity Type I clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with plastic flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies, LimitedIndia
Despina Pharma, Inc.
DRP-13927
May 18, 2028
MiborBortezomib
2 mg Powder for Solution for Injection (IV)USP Type I Vial with Bromo-Butyl Stopper and Red Colored Flip Off Seal x 5mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica, Inc.
DRP-9957
Nov 22, 2031
MiborBortezomib
3.5 mg Powder for Solution for Injection (IV)USP Type I Glass Vial x 10 mL (Box of 1's)
RxVAT-exempt
Celon Laboratories Pvt. Ltd.India
I.E. Medica Inc.
DRP-8001
Feb 2, 2030
MibzoBortezomib
3.5 mg Lyophilized Powder For InjectionUSP Type I Clear Glass Vial with Blue Flip-Off Seal x 10 mL (Box of 1’s)
RxVAT-exempt
MSN Laboratories Private LimitedIndia
Metro Drug Inc.
DR-XY48094
Jun 7, 2027
MyborteBortezomib
3.5 mg/vial Lyophilized Powder for I.V. Infusion10 mL USP Type I clear glass vial with dark grey bromobutyl rubber stopper and royal blue plastic flip-off seal (Box of 1's)
RxVAT-exempt
Dr. Reddy's Laboratories Ltd. (Formulation FTO-7)India
Dr. Reddy's Laboratories Philippines Inc.
DR-XY46740
Nov 13, 2029
MyzomibBortezomib
3.5 mg Lyophilized Powder for Injection (I.V./S.C.)Type I clear colorless glass vial with 20 mm dark grey bromobutyl rubber stopper and 20 mm brown flip-off aluminum seal (Box of 1's)
RxVAT-exempt
Mylan Laboratories Limited-OTLIndia
Viatris Pharmaceuticals, Inc.
DR-XY49180
Aug 21, 2029
MyzomibBortezomib
3.5 mg Lyophilized Powder for Injection (I.V./S.C.)Type I clear colorless glass vial with 20 mm dark grey bromobutyl rubber stopper and 20 mm brown flip-off aluminum seal (Box of 1's)
RxVAT-exempt
Mylan Laboratories Limited-OTLIndia
Viatris Pharmaceuticals, Inc.
DRP-15903
Aug 21, 2029
NeomibBortezomib
3.5 mg Lyophilized Powder for Injection (IV)Type I Flint Transparent Tubular Glass Vial x 15 mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Macropharma CorporationImporter: Ambica International Corporation
DRP-5513
Sep 15, 2029
NoneBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (I.V./S.C)USP Type I clear colorless glass vial with 20mm grey bromobutyl rubber stopper and 20 mm aluminum seal with plastic flip-off cap (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
2MG Incorporated
DRP-15764
Sep 12, 2029
OrbexaBortezomib
3.5 mg Lyophilized Powder for Injection (IV/SC)10 mL-Type I Clear Glass Vial x 1's (Box of 1's)
RxVAT-exempt
CSPC Ouyi Pharmaceutical Co., Ltd.China
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15984
Oct 8, 2029
SaphzomibBortezomib
2mg Lyophilized Powder for Injection (IV/SC)7.5 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Red Aluminum Flip Off Cap x l's (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-12479
Aug 17, 2027
SaphzomibBortezomib
3.5mg Lyophilized Powder For Injection (IV/SC)10 mL Type I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Red Aluminum Flip Off Cap xl's (Box of 1's)
RxVAT-exempt
Bruck Pharma Private LimitedIndia
Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-12480
Aug 17, 2027
TezobortBortezomib
2 mg Powder for Solution for Injection (IV/SC)USP Type -I glass vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Globo Asiatico Enterprises, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int'l Pvt. Ltd.
DRP-7643-01
Jan 26, 2028
TezominBortezomib
2.5 mg Lyophilized Powder For Injection (IV/SC)10mL-capacity USP Type I clear colorless glass vial with gray bromobutyl Rubber stopper with Plastic Aluminum Flipp-off Cap (Box of 1's) and colorless glass vial (Box of 1’s)
RxVAT-exempt
Korea United Pharm. Inc.Korea
Qualimed Pharma Inc.
DR-XY48564
Jan 17, 2028
TezominBortezomib
3.5 mg Lyophilized Powder For Injection (IV,SC)In USP Type I clear and colorless glass vial
RxVAT-exempt
Korea United Pharm Inc..Korea
Qualimed Pharma Inc.
DR-XY48577
Jan 23, 2028
TezoxilBortezomib
3.5 mg Powder for Solution for Injection (IV/SC)USP Type-I glass vial (Box of 1's)
RxVAT-exempt
Khandelwal Laboratories Pvt. Ltd.India
Globo Asiatico Enterprises, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int'l Pvt. Ltd.
DRP-7279-01
Jul 28, 2032
UnbrandedBortezomib
3.5 mg Lyophilized Powder for Injection (I.V./S.C.)USP Type I clear glass vial with 13 mm grey chlorobutyl rubber stopper and aluminum seal with 13 mm royal blue polypropylene flip-off cap (Box of 1's)
RxVAT-exempt
Gland Pharma LimitedIndia
Importer: Pfizer, Inc.
DRP-9149
Sep 18, 2037
Uniborte-3.5Bortezomib
3.5 mg Lyophilized Powder for Solution for Injection (I.V./S.C.)10 mL clear, moulded, Type I glass vial with bromobutyl rubber stopper, aluminum flip-off seal and green polypropylene cap (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
AGB Pharmaceutical Trading and Consultancy CorporationTrader: Unicare Healthsciences Pvt. Ltd.
DRP-9482
Jan 25, 2031
VelcadeBortezomib
3.5 mg Lyophilized Powder for Injection (IV/SC)USP Type I Borosilicate Flint Glass Vial x 10 mL (Box of 1’s)
RxVAT-exempt
BSP Pharmaceuticals S.P.AItaly
Zuellig Pharma CorporationImporter: Johnson & Johnson (Phils.) Inc.
DR-XY42460
Aug 29, 2028
Vortestar 3.5Bortezomib
3.5 mg Lyophilized Powder for Injection (IV/SC)10 mL-capacity USP Type I clear glass vial sealed with 20 mm slotted bromobutyl rubber stopper and 20 mm green flip off seal (Box of 1's)
RxVAT-exempt
Admac LifesciencesIndia
Pharmastar Int'l Trading Corp.
DRP-14495
Sep 13, 2028
Zomibest-2Bortezomib
2mg Lyophilized Powder for Injection (I.V.)10 mL clear glass vial USP type I stoppered with bromobutyl rubber plug and aluminum flip off seal having green color
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
Asa Life Philippines Limited, Inc.
DRP-6380
Oct 19, 2030
Zomibest-3.5Bortezomib
3.5 mg Lyophilized Powder for Injection (I.V.)10 mL Clear glass vial USP Type I stoppered with bromobutyl rubber plug and aluminium flip-off seal having red color (Box of 1's)
RxVAT-exempt
Adley Formulations Pvt. Ltd.India
ASA Life Philippines Limited, Inc.
DRP-6381
Oct 19, 2030
ZomicorBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (I.V./S.C.)10 mL- capacity Type I clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with plastic flip-off cap (Box of 1’s)
RxVAT-exempt
Venus Remedies, LimitedIndia
Epione Lifecare Inc.Importer: Despina Pharma, Inc.
DRP-13927-01
May 18, 2028
Zomod 3.5Bortezomib
3.5 mg Lyophilized Powder for Injection (IV/SC)10ml capacity Type I clear and colorless vial with gray butyl rubber stopper and aluminum seal fitted with red flip-off cap (Box of 1's)
RxVAT-exempt
INTAS PHARMACEUTICALS LIMITEDIndia
Importer: Accord Healthcare Limited - Philippine Branch Office
DRP-7337
Sep 14, 2027
Zomod-1Bortezomib
1mg Lyophilized Powder For Solution for Injection (IV)6 mL USP Type I clear flat bottom tubular glass vial with 13 mm grey butyl rubber stopper and 13 mm flip-off royal blue seal (Box of 1's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Importer: Accord Healthcare Limited-Philippine Branch Office
DRP-11437
Mar 14, 2027
ZortomibBortezomib
3.5 mg Lyophilized Powder for Solution for Injection (I.V./S.C.)10 mL clear, moulded, Type I glass vial with bromobutyl rubber stopper, aluminum flip-off seal and green polypropylene cap (Box of 1's)
RxVAT-exempt
ADMAC LifesciencesIndia
Ambica International Corporation
DRP-9481
Feb 2, 2031
ZyocadeBortezomib
3.5 mg Lyophilized Powder for Injection (IV)Type I Flint Transparent Tubular Glass Vial x 15 mL (Box of 1’s)
RxVAT-exempt
Getwell PharmaceuticalsIndia
Diafarm Inc.Importer: Ambica International Corporation
DRP-5513-02
Sep 15, 2029
(no brand name)Bortezomib
3.5 mg Lyophilized Powder for Injection (S.C./I.V.)Type I Clear Tubular Glass Vial with Gray Bromobutyl Rubber Stopper (Lyo-gloo) and Aluminum Seal (Lacquered) with Red PP Disk (Box of l's)
RxVAT-exempt
Eugia Pharma Specialties LimitedIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-11599
Mar 31, 2027
(no brand name)Bortezomib
3.5 mg Lyophilized Powder for Solution for Injection. (I.V./S.C.)10 mL-capacity Type I clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with plastic flip-off (Box of 1's)
RxVAT-exempt
Venus Remedies LimitedIndia
VE Pharma, Inc.Trader: Vexxa Lifesciences Pvt. Ltd.
DR-XY48724
May 11, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS For injection: Each single-dose vial of VELCADE contains 3.5 mg of bortezomib as a sterile lyophilized white to off-white powder for reconstitution and withdrawal of the appropriate individual patient dose [see Dosage and Administration (2.10)]. For injection: Single-dose vial contains 3.5 mg of bortezomib as lyophilized powder for reconstitution and withdrawal of the appropriate individual patient dose. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Peripheral Neuropathy: Manage with dose modification or discontinuation. (2.7)
  • Patients with pre-existing severe neuropathy should be treated with VELCADE only after careful risk-benefit assessment. (2.7, 5.1)
  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (5.2)
  • Cardiac Toxicity: Worsening of and development of cardiac failure has occurred. Closely monitor patients with existing heart disease or risk factors for heart disease. (5.3)
  • Pulmonary Toxicity: Acute respiratory syndromes have occurred. Monitor closely for new or worsening symptoms and consider interrupting VELCADE therapy. (5.4)
  • Posterior Reversible Encephalopathy Syndrome: Consider MRI imaging for onset of visual or neurological symptoms; discontinue VELCADE if suspected. (5.5)
  • Gastrointestinal Toxicity: Nausea, diarrhea, constipation, and vomiting may require use of antiemetic and antidiarrheal medications or fluid replacement. (5.6)
  • Thrombocytopenia and Neutropenia: Monitor complete blood counts regularly throughout treatment. (5.7)
  • Tumor Lysis Syndrome: Closely monitor patients with high tumor burden. (5.8)
  • Hepatic Toxicity: Monitor hepatic enzymes during treatment. Interrupt VELCADE therapy to assess reversibility. (5.9)
  • Thrombotic Microangiopathy: Monitor for signs and symptoms. Discontinue VELCADE if suspected. (…
5.1 Peripheral Neuropathy

5.1 Peripheral Neuropathy VELCADE treatment causes a peripheral neuropathy that is predominantly sensory; however, cases of severe sensory and motor peripheral neuropathy have been reported. Patients with pre-existing symptoms (numbness, pain or a burning feeling in the feet or hands) and/or signs of peripheral neuropathy may experience worsening peripheral neuropathy (including ≥Grade 3) during treatment with VELCADE.

Patients should be monitored for symptoms of neuropathy, such as a burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain or weakness. In the Phase 3 relapsed multiple myeloma trial comparing VELCADE subcutaneous vs intravenous, the incidence of Grade ≥2 peripheral neuropathy was 24% for subcutaneous and 39% for intravenous.

Grade ≥3 peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 15% in the intravenous treatment group [see Adverse Reactions (6.1)]. Starting VELCADE subcutaneously may be considered for patients with pre-existing or at high risk of peripheral neuropathy. Patients experiencing new or worsening peripheral neuropathy during VELCADE therapy may require a decrease in the dose and/or a less dose-intense schedule [see Dosage and Administration (2.7)].

In the VELCADE vs dexamethasone Phase 3 relapsed multiple myeloma study, improvement in or resolution of peripheral neuropathy was reported in 48% of patients with ≥Grade 2 peripheral neuropathy following dose adjustment or interruption. Improvement in or resolution of peripheral neuropathy was reported in 73% of patients who discontinued due to Grade 2 neuropathy or who had ≥Grade 3 peripheral neuropathy in the Phase 2 multiple myeloma studies.

The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma.

5.2 Hypotension

5.2 Hypotension The incidence of hypotension (postural, orthostatic, and hypotension NOS) was 8% [see Adverse Reactions (6.1)]. These events are observed throughout therapy. Patients with a history of syncope, patients receiving medications known to be associated with hypotension, and patients who are dehydrated may be at increased risk of hypotension.

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics.

5.3 Cardiac Toxicity

5.3 Cardiac Toxicity Acute development or exacerbation of congestive heart failure and new onset of decreased left ventricular ejection fraction have occurred during VELCADE therapy, including reports in patients with no risk factors for decreased left ventricular ejection fraction [see Adverse Reactions (6.1)]. Patients with risk factors for, or existing heart disease should be frequently monitored.

In the relapsed multiple myeloma study of VELCADE vs dexamethasone, the incidence of any treatment-related cardiac disorder was 8% and 5% in the VELCADE and dexamethasone groups, respectively. The incidence of adverse reactions suggestive of heart failure (acute pulmonary edema, pulmonary edema, cardiac failure, congestive cardiac failure, cardiogenic shock) was ≤1% for each individual reaction in the VELCADE group.

In the dexamethasone group the incidence was ≤1% for cardiac failure and congestive cardiac failure; there were no reported reactions of acute pulmonary edema, pulmonary edema, or cardiogenic shock. There have been isolated cases of QT-interval prolongation in clinical studies; causality has not been established.

5.4 Pulmonary Toxicity Acute Respiratory Distress

5.4 Pulmonary Toxicity Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration have occurred in patients receiving VELCADE. Some of these events have been fatal. In a clinical trial, the first two patients given high-dose cytarabine (2 g/m 2 per day) by continuous infusion with daunorubicin and VELCADE for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy.

There have been reports of pulmonary hypertension associated with VELCADE administration in the absence of left heart failure or significant pulmonary disease. In the event of new or worsening cardiopulmonary symptoms, consider interrupting VELCADE until a prompt and comprehensive diagnostic evaluation is conducted.

5.5 Posterior Reversible Encephalopathy Syndrome (PRES)

5.5 Posterior Reversible Encephalopathy Syndrome (PRES) Posterior Reversible Encephalopathy Syndrome (PRES; formerly termed Reversible Posterior Leukoencephalopathy Syndrome (RPLS)) has occurred in patients receiving VELCADE. PRES is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances.

Brain imaging, preferably MRI (Magnetic Resonance Imaging), is used to confirm the diagnosis. In patients developing PRES, discontinue VELCADE. The safety of reinitiating VELCADE therapy in patients previously experiencing PRES is not known.

5.6 Gastrointestinal Toxicity

5.6 Gastrointestinal Toxicity VELCADE treatment can cause nausea, diarrhea, constipation, and vomiting [see Adverse Reactions (6.1)] sometimes requiring use of antiemetic and antidiarrheal medications. Ileus can occur. Fluid and electrolyte replacement should be administered to prevent dehydration. Interrupt VELCADE for severe symptoms.

5.7 Thrombocytopenia/Neutropenia

5.7 Thrombocytopenia/Neutropenia VELCADE is associated with thrombocytopenia and neutropenia that follow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recovering prior to initiation of the subsequent cycle. The cyclical pattern of platelet and neutrophil decreases and recovery remain consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in the treatment regimens studied.

Monitor complete blood counts (CBC) frequently during treatment with VELCADE. Measure platelet counts prior to each dose of VELCADE. Adjust dose/schedule for thrombocytopenia [see Dosage and Administration (2.6)]. Gastrointestinal and intracerebral hemorrhage has occurred during thrombocytopenia in association with VELCADE.

Support with transfusions and supportive care, according to published guidelines. In the single agent, relapsed multiple myeloma study of VELCADE vs dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pretreatment platelet count is shown in Table 8.

The incidence of bleeding (≥Grade 3) was 2% on the VELCADE arm and was <1% in the dexamethasone arm. Table 8: Severity of Thrombocytopenia Related to Pretreatment Platelet Count in the Relapsed Multiple Myeloma Study of VELCADE vs Dexamethasone Pretreatment Platelet Count A baseline platelet count of 50,000/µL was required for study eligibility Number of Patients (N=331) Data were missing at baseline for one patient Number (%) of Patients with Platelet Count <10,000/µL Number (%) of Patients with Platelet Count 10,000 to 25,000/µL ≥75,000/µL 309 8 (3%) 36 (12%) ≥50,000/µL to <75,000/µL 14 2 (14%) 11 (79%) ≥10,000/µL to <50,000/µL 7 1 (14%) 5 (71%) In the combination study of VELCADE with rituximab, cyclophosphamide, doxorubicin and prednisone (VcR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12.

The incidence of bleeding events (≥Grade 3) was 1.7% in the VcR-CAP arm (four patients) and was 1.2% in the R-CHOP arm (three patients). Platelet transfusions were given to 23% of the patients in the VcR-CAP arm and 3% of the patients in the R-CHOP arm. The incidence of neutropenia (≥Grade 4) was 70% in the VcR-CAP arm and was 52% in the R-CHOP arm.

The incidence of febrile neutropenia (≥Grade 4) was 5% in the VcR-CAP arm and was 6% in the R-CHOP arm. Myeloid growth factor support was provided at a rate of 78% in the VcR-CAP arm and 61% in the R-CHOP arm.

5.8 Tumor Lysis Syndrome

5.8 Tumor Lysis Syndrome Tumor lysis syndrome has been reported with VELCADE therapy. Patients at risk of tumor lysis syndrome are those with high tumor burden prior to treatment. Monitor patients closely and take appropriate precautions.

5.9 Hepatic Toxicity

5.9 Hepatic Toxicity Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Other reported hepatic reactions include hepatitis, increases in liver enzymes, and hyperbilirubinemia. Interrupt VELCADE therapy to assess reversibility.

There is limited rechallenge information in these patients.

5.10 Thrombotic Microangiopathy

5.10 Thrombotic Microangiopathy Cases, sometimes fatal, of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported in the postmarketing setting in patients who received VELCADE. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop VELCADE and evaluate.

If the diagnosis of TTP/HUS is excluded, consider restarting VELCADE. The safety of reinitiating VELCADE therapy in patients previously experiencing TTP/HUS is not known.

5.11 Embryo-Fetal Toxicity

5.11 Embryo-Fetal Toxicity Based on the mechanism of action and findings in animals, VELCADE can cause fetal harm when administered to a pregnant woman. Bortezomib administered to rabbits during organogenesis at a dose approximately 0.5 times the clinical dose of 1.3 mg/m 2 based on body surface area caused postimplantation loss and a decreased number of live fetuses [see Use in Specific Populations (8.1)].

Advise females of reproductive potential to use effective contraception during treatment with VELCADE and for seven months following treatment. Advise males with female partners of reproductive potential to use effective contraception during treatment with VELCADE and for four months following treatment. If VELCADE is used during pregnancy or if the patient becomes pregnant during VELCADE treatment, the patient should be apprised of the potential risk to the fetus [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].

Drug interactions

Drug interactions (US label) US FDA label
  • Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (7.1)
  • Strong CYP3A4 Inducers: Avoid concomitant use. (7.1)
7.1 Effects of Other Drugs

7.1 Effects of Other Drugs on VELCADE Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [see Clinical Pharmacology (12.3)] which may decrease VELCADE efficacy. Avoid coadministration with strong CYP3A4 inducers. Strong CYP3A4 Inhibitors Coadministration with a strong CYP3A4 inhibitor increases the exposure of bortezomib [see Clinical Pharmacology (12.3)] which may increase the risk of VELCADE toxicities.

Monitor patients for signs of bortezomib toxicity and consider a bortezomib dose reduction if bortezomib must be given in combination with strong CYP3A4 inhibitors.

7.2 Drugs Without Clinically Significant Interactions

7.2 Drugs Without Clinically Significant Interactions with VELCADE No clinically significant drug interactions have been observed when VELCADE was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism Bortezomib is primarily oxidatively metabolized to several inactive metabolites in vitro via cytochrome P450 (CYP) enzymes 3A4, CYP2C19, and CYP1A2, and to a lesser extent by CYP2D6 and CYP2C9.

Drug Interaction Studies Clinical Studies No clinically significant differences in bortezomib pharmacokinetics were observed when coadministered with dexamethasone (weak CYP3A4 inducer), omeprazole (strong CYP2C19 inhibitor), or melphalan in combination with prednisone.

Strong CYP3A4 Inhibitor Coadministration with ketoconazole (strong CYP3A4 inhibitor) increased bortezomib exposure by 35%.

Strong CYP3A4 Inducer Coadministration with rifampin (strong CYP3A4 inducer) decreased bortezomib exposure by approximately 45%.

In Vitro Studies Bortezomib may inhibit CYP2C19 activity and increase exposure to drugs that are substrates for this enzyme.

7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use.

( 7.1 ) Strong CYP3A4 Inducers: Avoid concomitant use.

( 7.1 ) 7.1 Effects of Other Drugs on VELCADE Strong CYP3A4 Inducers Coadministration with a strong CYP3A4 inducer decreases the exposure of bortezomib [see Clinical Pharmacology (12.3) ] which may decrease VELCADE efficacy.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are also discussed in other sections of the labeling: Peripheral Neuropathy [see Warnings and Precautions (5.1)] Hypotension [see Warnings and Precautions (5.2)] Cardiac Toxicity [see Warnings and Precautions (5.3)] Pulmonary Toxicity [see Warnings and Precautions (5.4)] Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.5)] Gastrointestinal Toxicity [see Warnings and Precautions (5.6)] Thrombocytopenia/Neutropenia [see Warnings and Precautions (5.7)] Tumor Lysis Syndrome [see Warnings and Precautions (5.8)] Hepatic Toxicity [see Warnings and Precautions (5.9)] Thrombotic Microangiopathy [see Warnings and Precautions (5.10)] Most commonly reported adverse reactions (incidence ≥20%) in clinical studies include nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-866-VELCADE or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Summary of Clinical Trial in Patients with Previously Untreated Multiple Myeloma Table 9 describes safety data from 340 patients with previously untreated multiple myeloma who received VELCADE (1.3 mg/m 2) administered intravenously in combination with melphalan (9 mg/m 2) and prednisone (60 mg/m 2) in a prospective randomized study.

The safety profile of VELCADE in combination with melphalan/prednisone is consistent with the known safety profiles of both VELCADE and melphalan/prednisone. Table 9: Most Commonly Reported Adverse Reactions (≥10% in the VELCADE, Melphalan and Prednisone Arm) with Grades 3 and ≥4 Intensity in the Previously Untreated Multiple Myeloma Study VELCADE, Melphalan and Prednisone Melphalan and Prednisone (n=340) (n=337) Body System Total Toxicity Grade, n (%) Total Toxicity Grade, n (%) Adverse Reaction n (%) 3 ≥4 n (%) 3 ≥4 Blood and Lymphatic System Disorders Thrombocytopenia 164 (48) 60 (18) 57 (17) 140 (42) 48 (14) 39 (12) Neutropenia 160 (47) 101 (30) 33 (10) 143 (42) 77 (23) 42 (12) Anemia 109 (32) 41 (12) 4 (1) 156 (46) 61 (18) 18 (5) Leukopenia 108 (32) 64 (19) 8 (2) 93 (28) 53 (16) 11 (3) Lymphopenia 78 (23) 46 (14) 17 (5) 51 (15) 26 (8) 7 (2) Gastrointestinal Disorders Nausea 134 (39) 10 (3) 0 70 (21) 1 (<1) 0 Diarrhea 119 (35) 19 (6) 2 (1) 20 (6) 1 (<1) 0 Vomiting 87 (26) 13 (4) 0 41 (12) 2 (1) 0 Constipation 77 (23) 2 (1) 0 14 (4) 0 0 Abdominal pain upper 34 (10) 1 (<1) 0 20 (6) 0 0 Nervous System Disorders Peripheral neuropathy Represents High Level Term Peripheral Neuropathies NEC 156 (46) 42 (12) 2 (1) 4 (1) 0 0 Neuralgia 117 (34) 27 (8) 2 (1) 1 (<1) 0 0 Paresthesia 42 (12) 6 (2) 0 4 (1) 0 0 General Disorders and Administration Site Conditions Fatigue 85 (25) 19 (6) 2 (1) 48 (14) 4 (1) 0 Asthenia 54 (16) 18 (5) 0 23 (7) 3 (1) 0 Pyrexia 53 (16) 4 (1) 0 19 (6) 1 (<1) 1 (<1) Infections and Infestations Herpes Zoster 39 (11) 11 (3) 0 9 (3) 4 (1) 0 Metabolism and Nutrition Disorders Anorexia 64 (19) 6 (2) 0 19 (6) 0 0 Skin and Subcutaneous Tissue Disorders Rash 38 (11) 2 (1) 0 7 (2) 0 0 Psychiatric Disorders Insomnia 35 (10) 1 (<1) 0 21 (6) 0 0 Relapsed Multiple Myeloma Randomized Study of VELCADE vs Dexamethasone The safety data described below and in Table 10 reflect exposure to either VELCADE (n=331) or dexamethasone (n=332) in a study of patients with relapsed multiple myeloma.

VELCADE was administered intravenously at doses of 1.3 mg/m 2 twice weekly for two out of three weeks (21 day cycle). After eight, 21 day cycles patients continued therapy for three, 35 day cycles on a weekly schedule. Duration of treatment was up to 11 cycles (nine months) with a median duration of six cycles (4.1 months).

For inclusion in the trial, patients must have had measurable disease and one to three prior therapies. There was no upper age limit for entry. Creatinine clearance could be as low as 20 mL/min and bilirubin levels as high as 1.5 times the upper limit of normal. The overall frequency of adverse reactions was similar in men and women, and in patients <65 and ≥65 years of age.

Most patients were Caucasian [see Clinical Studies (14.1)]. Among the 331 VELCADE-treated patients, the most commonly reported (>20%) adverse reactions overall were nausea (52%), diarrhea (52%), fatigue (39%), peripheral neuropathies (35%), thrombocytopenia (33%), constipation (30%), vomiting (29%), and anorexia (21%). The most commonly reported (>20%) adverse reaction reported among the 332 patients in the dexamethasone group was fatigue (25%).

Eight percent (8%) of patients in the VELCADE-treated arm experienced a Grade 4 adverse reaction; the most common reactions were thrombocytopenia (4%) and neutropenia (2%). Nine percent (9%) of dexamethasone-treated patients experienced a Grade 4 adverse reaction. All individual dexamethasone-related Grade 4 adverse reactions were less than 1%.

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of VELCADE vs Dexamethasone Serious adverse reactions are defined as any reaction that results in death, is life-threatening, requires hospitalization or prolongs a current hospitalization, results in a significant disability, or is deemed to be an important medical event. A total of 80 (24%) patients from the VELCADE treatment arm experienced a serious adverse reaction during the study, as did 83 (25%) dexamethasone-treated patients.

The most commonly reported serious adverse reactions in the VELCADE treatment arm were diarrhea (3%), dehydration, herpes zoster, pyrexia, nausea, vomiting, dyspnea, and thrombocytopenia (2% each). In the dexamethasone treatment group, the most commonly reported serious adverse reactions were pneumonia (4%), hyperglycemia (3%), pyrexia, and psychotic disorder (2% each).

A total of 145 patients, including 84 (25%) of 331 patients in the VELCADE treatment group and 61 (18%) of 332 patients in the dexamethasone treatment group were discontinued from treatment due to adverse reactions. Among the 331 VELCADE-treated patients, the most commonly reported adverse reaction leading to discontinuation was peripheral neuropathy (8%).

Among the 332 patients in the dexamethasone group, the most commonly reported adverse reactions leading to treatment discontinuation were psychotic disorder and hyperglycemia (2% each). Four deaths were considered to be VELCADE-related in this relapsed multiple myeloma study: one case each of cardiogenic shock, respiratory insufficiency, congestive heart failure and cardiac arrest.

Four deaths were considered dexamethasone-related: two cases of sepsis, one case of bacterial meningitis, and one case of sudden death at home. Most Commonly Reported Adverse Reactions in the Relapsed Multiple Myeloma Study of VELCADE vs Dexamethasone The most common adverse reactions from the relapsed multiple myeloma study are shown in Table 10.

All adverse reactions with incidence ≥10% in the VELCADE arm are included. Table 10: Most Commonly Reported Adverse Reactions (≥10% in VELCADE Arm), with Grades 3 and 4 Intensity in the Relapsed Multiple Myeloma Study of VELCADE vs Dexamethasone (N=663) VELCADE (N=331) Dexamethasone (N=332) Adverse Reactions All Grade 3 Grade 4 All Grade 3 Grade 4 Any Adverse Reactions 324 (98) 193 (58) 28 (8) 297 (89) 110 (33) 29 (9) Nausea 172 (52) 8 (2) 0 31 (9) 0 0 Diarrhea NOS 171 (52) 22 (7) 0 36 (11) 2 (<1) 0 Fatigue 130 (39) 15 (5) 0 82 (25) 8 (2) 0 Peripheral neuropathies Represents High Level Term Peripheral Neuropathies NEC 115 (35) 23 (7) 2 (<1) 14 (4) 0 1 (<1) Thrombocytopenia 109 (33) 80 (24) 12 (4) 11 (3) 5 (2) 1 (<1) Constipation 99 (30) 6 (2) 0 27 (8) 1 (<1) 0 Vomiting NOS 96 (29) 8 (2) 0 10 (3) 1 (<1) 0 Anorexia 68 (21) 8 (2) 0 8 (2) 1 (<1) 0 Pyrexia 66 (20) 2 (<1) 0 21 (6) 3 (<1) 1 (<1) Paresthesia 64 (19) 5 (2) 0 24 (7) 0 0 Anemia NOS 63 (19) 20 (6) 1 (<1) 21 (6) 8 (2) 0 Headache NOS 62 (19) 3 (<1) 0 23 (7) 1 (<1) 0 Neutropenia 58 (18) 37 (11) 8 (2) 1 (<1) 1 (<1) 0 Rash NOS 43 (13) 3 (<1) 0 7 (2) 0 0 Appetite decreased NOS 36 (11) 0 0 12 (4) 0 0 Dyspnea NOS 35 (11) 11 (3) 1 (<1) 37 (11) 7 (2) 1 (<1) Abdominal pain NOS 35 (11) 5 (2) 0 7 (2) 0 0 Weakness 34 (10) 10 (3) 0 28 (8) 8 (2) 0 Safety Experience from the Phase 2 Open-Label Extension Study in Relapsed Multiple Myeloma In the Phase 2 extension study of 63 patients, no new cumulative or new long-term toxicities were observed with prolonged VELCADE treatment.

These patients were treated for a total of 5.3 to 23 months, including time on VELCADE in the prior VELCADE study [see Clinical Studies (14.1)]. Safety Experience from the Phase 3 Open-Label Study of VELCADE Subcutaneous vs Intravenous in Relapsed Multiple Myeloma The safety and efficacy of VELCADE administered subcutaneously were evaluated in one Phase 3 study at the recommended dose of 1.3 mg/m 2.

This was a randomized, comparative study of VELCADE subcutaneous vs intravenous in 222 patients with relapsed multiple myeloma. The safety data described below and in Table 11 reflect exposure to either VELCADE subcutaneous (N=147) or VELCADE intravenous (N=74) [see Clinical Studies (14.1)]. Table 11: Most Commonly Reported Adverse Reactions (≥10%), with Grade 3 and ≥4 Intensity in the Relapsed Multiple Myeloma Study (N=221) of VELCADE Subcutaneous vs Intravenous Subcutaneous Intravenous (N=147) (N=74) Body System Total Toxicity Grade, n (%) Total Toxicity Grade, n (%) Adverse Reaction n (%) 3 ≥4 n (%) 3 ≥4 Note: Safety population: 147 patients in the subcutaneous treatment group and 74 patients in the intravenous treatment group who received at least one dose of study medication Blood and Lymphatic System Disorders Anemia 28 (19) 8 (5) 0 17 (23) 3 (4) 0 Leukopenia 26 (18) 8 (5) 0 15 (20) 4 (5) 1 (1) Neutropenia 34 (23) 15 (10) 4 (3) 20 (27) 10 (14) 3 (4) Thrombocytopenia 44 (30) 7 (5) 5 (3) 25 (34) 7 (9) 5 (7) Gastrointestinal Disorders Diarrhea 28 (19) 1 (1) 0 21 (28) 3 (4) 0 Nausea 24 (16) 0 0 10 (14) 0 0 Vomiting 13 (9) 3 (2) 0 8 (11) 0 0 General Disorders and Administration Site Conditions Asthenia 10 (7) 1 (1) 0 12 (16) 4 (5) 0 Fatigue 11 (7) 3 (2) 0 11 (15) 3 (4) 0 Pyrexia 18 (12) 0 0 6 (8) 0 0 Nervous System Disorders Neuralgia 34 (23) 5 (3) 0 17 (23) 7 (9) 0 Peripheral neuropathies Represents High Level Term Peripheral Neuropathies NEC 55 (37) 8 (5) 1 (1) 37 (50) 10 (14) 1 (1) In general, safety data were similar for the subcutaneous and intravenous treatment groups.

Differences were observed in the rates of some Grade ≥3 adverse reactions. Differences of ≥5% were reported in neuralgia (3% subcutaneous vs 9% intravenous), peripheral neuropathies (6% subcutaneous vs 15% intravenous), neutropenia (13% subcutaneous vs 18% intravenous), and thrombocytopenia (8% subcutaneous vs 16% intravenous).

A local reaction was reported in 6% of patients in the subcutaneous group, mostly redness. Only two (1%) patients were reported as having severe reactions, one case of pruritus and one case of redness. Local reactions led to reduction in injection concentration in one patient and drug discontinuation in one patient. Local reactions resolved in a median of six days.

Dose reductions occurred due to adverse reactions in 31% of patients in the subcutaneous treatment group compared with 43% of the intravenously-treated patients. The most common adverse reactions leading to a dose reduction included peripheral sensory neuropathy (17% in the subcutaneous treatment group compared with 31% in the intravenous treatment group); and neuralgia (11% in the subcutaneous treatment group compared with 19% in the intravenous treatment group).

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Relapsed Multiple Myeloma Study of VELCADE Subcutaneous vs Intravenous The incidence of serious adverse reactions was similar for the subcutaneous treatment group (20%) and the intravenous treatment group (19%). The most commonly reported serious adverse reactions in the subcutaneous treatment arm were pneumonia and pyrexia (2% each).

In the intravenous treatment group, the most commonly reported serious adverse reactions were pneumonia, diarrhea, and peripheral sensory neuropathy (3% each). In the subcutaneous treatment group, 27 patients (18%) discontinued study treatment due to an adverse reaction compared with 17 patients (23%) in the intravenous treatment group.

Among the 147 subcutaneously-treated patients, the most commonly reported adverse reactions leading to discontinuation were peripheral sensory neuropathy (5%) and neuralgia (5%). Among the 74 patients in the intravenous treatment group, the most commonly reported adverse reactions leading to treatment discontinuation were peripheral sensory neuropathy (9%) and neuralgia (9%).

Two patients (1%) in the subcutaneous treatment group and one (1%) patient in the intravenous treatment group died due to an adverse reaction during treatment. In the subcutaneous group the causes of death were one case of pneumonia and one case of sudden death. In the intravenous group the cause of death was coronary artery insufficiency.

Safety Experience from the Clinical Trial in Patients with Previously Untreated Mantle Cell Lymphoma Table 12 describes safety data from 240 patients with previously untreated mantle cell lymphoma who received VELCADE (1.3 mg/m 2) administered intravenously in combination with rituximab (375 mg/m 2), cyclophosphamide (750 mg/m 2), doxorubicin (50 mg/m 2), and prednisone (100 mg/m 2) (VcR-CAP) in a prospective randomized study. Infections were reported for 31% of patients in the VcR-CAP arm and 23% of the patients in the comparator (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) arm, including the predominant preferred term of pneumonia (VcR-CAP 8% vs R-CHOP 5%).

Table 12: Most Commonly Reported Adverse Reactions (≥5%) with Grades 3 and ≥4 Intensity in the Previously Untreated Mantle Cell Lymphoma Study VcR-CAP (n=240) R-CHOP (n=242) Body System Adverse Reactions All n (%) Toxicity Grade 3 n (%) Toxicity Grade ≥4 n (%) All n (%) Toxicity Grade 3 n (%) Toxicity Grade ≥4 n (%) Key: R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP = VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone. Blood and Lymphatic System Disorders Neutropenia 209 (87) 32 (13) 168 (70) 172 (71) 31 (13) 125 (52) Leukopenia 116 (48) 34 (14) 69 (29) 87 (36) 39 (16) 27 (11) Anemia 106 (44) 27 (11) 4 (2) 71 (29) 23 (10) 4 (2) Thrombocytopenia 172 (72) 59 (25) 76 (32) 42 (17) 9 (4) 3 (1) Febrile neutropenia 41 (17) 24 (10) 12 (5) 33 (14) 17 (7) 15 (6) Lymphopenia 68 (28) 25 (10) 36 (15) 28 (12) 15 (6) 2 (1) Nervous System Disorders Peripheral neuropathy Represents High Level Term Peripheral Neuropathies NEC 71 (30) 17 (7) 1 (<1) 65 (27) 10 (4) 0 Hypoesthesia 14 (6) 3 (1) 0 13 (5) 0 0 Paresthesia 14 (6) 2 (1) 0 11 (5) 0 0 Neuralgia 25 (10) 9 (4) 0 1 (<1) 0 0 General Disorders and Administration Site Conditions Fatigue 43 (18) 11 (5) 1 (<1) 38 (16) 5 (2) 0 Pyrexia 48 (20) 7 (3) 0 23 (10) 5 (2) 0 Asthenia 29 (12) 4 (2) 1 (<1) 18 (7) 1 (<1) 0 Edema peripheral 16 (7) 1 (<1) 0 13 (5) 0 0 Gastrointestinal Disorders Nausea 54 (23) 1 (<1) 0 28 (12) 0 0 Constipation 42 (18) 1 (<1) 0 22 (9) 2 (1) 0 Stomatitis 20 (8) 2 (1) 0 19 (8) 0 1 (<1) Diarrhea 59 (25) 11 (5) 0 11 (5) 3 (1) 1 (<1) Vomiting 24 (10) 1 (<1) 0 8 (3) 0 0 Abdominal distension 13 (5) 0 0 4 (2) 0 0 Infections and Infestations Pneumonia 20 (8) 8 (3) 5 (2) 11 (5) 5 (2) 3 (1) Skin and Subcutaneous Tissue Disorders Alopecia 31 (13) 1 (<1) 1 (<1) 33 (14) 4 (2) 0 Metabolism and Nutrition Disorders Hyperglycemia 10 (4) 1 (<1) 0 17 (7) 10 (4) 0 Decreased appetite 36 (15) 2 (1) 0 15 (6) 1 (<1) 0 Vascular Disorders Hypertension 15 (6) 1 (<1) 0 3 (1) 0 0 Psychiatric Disorders Insomnia 16 (7) 1 (<1) 0 8 (3) 0 0 The incidence of herpes zoster reactivation was 4.6% in the VcR-CAP arm and 0.8% in the R-CHOP arm.

Antiviral prophylaxis was mandated by protocol amendment. The incidences of Grade ≥3 bleeding events were similar between the two arms (four patients in the VcR-CAP arm and three patients in the R-CHOP arm). All of the Grade ≥3 bleeding events resolved without sequelae in the VcR-CAP arm. Adverse reactions leading to discontinuation occurred in 8% of patients in VcR-CAP group and 6% of patients in R-CHOP group.

In the VcR-CAP group, the most commonly reported adverse reaction leading to discontinuation was peripheral sensory neuropathy (1%; three patients). The most commonly reported adverse reaction leading to discontinuation in the R-CHOP group was febrile neutropenia (<1%; two patients). Integrated Summary of Safety (Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma) Safety data from Phase 2 and 3 studies of single agent VELCADE 1.3 mg/m 2 /dose twice weekly for two weeks followed by a ten day rest period in 1163 patients with previously-treated multiple myeloma (N=1008) and previously-treated mantle cell lymphoma (N=155) were integrated and tabulated.

This analysis does not include data from the Phase 3 open-label study of VELCADE subcutaneous vs intravenous in relapsed multiple myeloma. In the integrated studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported (>20%) adverse reactions were nausea (49%), diarrhea (46%), asthenic conditions including fatigue (41%) and weakness (11%), peripheral neuropathies (38%), thrombocytopenia (32%), vomiting (28%), constipation (25%), and pyrexia (21%).

Eleven percent (11%) of patients experienced at least one episode of ≥Grade 4 toxicity, most commonly thrombocytopenia (4%) and neutropenia (2%). In the Phase 2 relapsed multiple myeloma clinical trials of VELCADE administered intravenously, local skin irritation was reported in 5% of patients, but extravasation of VELCADE was not associated with tissue damage.

Serious Adverse Reactions and Adverse Reactions Leading to Treatment Discontinuation in the Integrated Summary of Safety A total of 26% of patients experienced a serious adverse reaction during the studies. The most commonly reported serious adverse reactions included diarrhea, vomiting and pyrexia (3% each), nausea, dehydration, and thrombocytopenia (2% each) and pneumonia, dyspnea, peripheral neuropathies, and herpes zoster (1% each).

Adverse reactions leading to discontinuation occurred in 22% of patients. The reasons for discontinuation included peripheral neuropathy (8%), and fatigue, thrombocytopenia, and diarrhea (2% each). In total, 2% of the patients died and the cause of death was considered by the investigator to be possibly related to study drug: including reports of cardiac arrest, congestive heart failure, respiratory failure, renal failure, pneumonia and sepsis.

Most Commonly Reported Adverse Reactions in the Integrated Summary of Safety The most common adverse reactions are shown in Table 13. All adverse reactions occurring at ≥10% are included. In the absence of a randomized comparator arm, it is often not possible to distinguish between adverse events that are drug-caused and those that reflect the patient's underlying disease.

Please see the discussion of specific adverse reactions that follows. Table 13: Most Commonly Reported (≥10% Overall) Adverse Reactions in Integrated Analyses of Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma Studies Using the 1.3 mg/m 2 Dose (N=1163) All Patients (N=1163) Multiple Myeloma (N=1008) Mantle Cell Lymphoma (N=155) Adverse Reactions All ≥Grade 3 All ≥Grade 3 All ≥Grade 3 Nausea 567 (49) 36 (3) 511 (51) 32 (3) 56 (36) 4 (3) Diarrhea NOS 530 (46) 83 (7) 470 (47) 72 (7) 60 (39) 11 (7) Fatigue 477 (41) 86 (7) 396 (39) 71 (7) 81 (52) 15 (10) Peripheral neuropathies Represents High Level Term Peripheral Neuropathies NEC 443 (38) 129 (11) 359 (36) 110 (11) 84 (54) 19 (12) Thrombocytopenia 369 (32) 295 (25) 344 (34) 283 (28) 25 (16) 12 (8) Vomiting NOS 321 (28) 44 (4) 286 (28) 40 (4) 35 (23) 4 (3) Constipation 296 (25) 17 (1) 244 (24) 14 (1) 52 (34) 3 (2) Pyrexia 249 (21) 16 (1) 233 (23) 15 (1) 16 (10) 1 (<1) Anorexia 227 (20) 19 (2) 205 (20) 16 (2) 22 (14) 3 (2) Anemia NOS 209 (18) 65 (6) 190 (19) 63 (6) 19 (12) 2 (1) Headache NOS 175 (15) 8 (<1) 160 (16) 8 (<1) 15 (10) 0 Neutropenia 172 (15) 121 (10) 164 (16) 117 (12) 8 (5) 4 (3) Rash NOS 156 (13) 8 (<1) 120 (12) 4 (<1) 36 (23) 4 (3) Paresthesia 147 (13) 9 (<1) 136 (13) 8 (<1) 11 (7) 1 (<1) Dizziness (excl vertigo) 129 (11) 13 (1) 101 (10) 9 (<1) 28 (18) 4 (3) Weakness 124 (11) 31 (3) 106 (11) 28 (3) 18 (12) 3 (2) Description of Selected Adverse Reactions from the Integrated Phase 2 and 3 Relapsed Multiple Myeloma and Phase 2 Relapsed Mantle Cell Lymphoma Studies Gastrointestinal Toxicity A total of 75% of patients experienced at least one gastrointestinal disorder.

The most common gastrointestinal disorders included nausea, diarrhea, constipation, vomiting, and appetite decreased. Other gastrointestinal disorders included dyspepsia and dysgeusia. Grade 3 adverse reactions occurred in 14% of patients; ≥Grade 4 adverse reactions were ≤1%. Gastrointestinal adverse reactions were considered serious in 7% of patients.

Four percent (4%) of patients discontinued due to a gastrointestinal adverse reaction. Nausea was reported more often in patients with multiple myeloma (51%) compared to patients with mantle cell lymphoma (36%). Thrombocytopenia Across the studies, VELCADE-associated thrombocytopenia was characterized by a decrease in platelet count during the dosing period (Days 1 to 11) and a return toward baseline during the ten day rest period during each treatment cycle.

Overall, thrombocytopenia was reported in 32% of patients. Thrombocytopenia was Grade 3 in 22%, ≥Grade 4 in 4%, and serious in 2% of patients, and the reaction resulted in VELCADE discontinuation in 2% of patients [see Warnings and Precautions (5.7)]. Thrombocytopenia was reported more often in patients with multiple myeloma (34%) compared to patients with mantle cell lymphoma (16%).

The incidence of ≥Grade 3 thrombocytopenia also was higher in patients with multiple myeloma (28%) compared to patients with mantle cell lymphoma (8%). Peripheral Neuropathy Overall, peripheral neuropathies occurred in 38% of patients. Peripheral neuropathy was Grade 3 for 11% of patients and ≥Grade 4 for <1% of patients.

Eight percent (8%) of patients discontinued VELCADE due to peripheral neuropathy. The incidence of peripheral neuropathy was higher among patients with mantle cell lymphoma (54%) compared to patients with multiple myeloma (36%). In the VELCADE vs dexamethasone Phase 3 relapsed multiple myeloma study, among the 62 VELCADE-treated patients who experienced ≥Grade 2 peripheral neuropathy and had dose adjustments, 48% had improved or resolved with a median of 3.8 months from first onset.

In the Phase 2 relapsed multiple myeloma studies, among the 30 patients who experienced Grade 2 peripheral neuropathy resulting in discontinuation or who experienced ≥Grade 3 peripheral neuropathy, 73% reported improvement or resolution with a median time of 47 days to improvement of one grade or more from the last dose of VELCADE. Hypotension The incidence of hypotension (postural, orthostatic and hypotension NOS) was 8% in patients treated with VELCADE.

Hypotension was Grade 1 or 2 in the majority of patients and Grade 3 in 2% and ≥Grade 4 in <1%. Two percent (2%) of patients had hypotension reported as a serious adverse reaction, and 1% discontinued due to hypotension. The incidence of hypotension was similar in patients with multiple myeloma (8%) and those with mantle cell lymphoma (9%).

In addition, <1% of patients experienced hypotension associated with a syncopal reaction. Neutropenia Neutrophil counts decreased during the VELCADE dosing period (Days 1 to 11) and returned toward baseline during the ten day rest period during each treatment cycle. Overall, neutropenia occurred in 15% of patients and was Grade 3 in 8% of patients and ≥Grade 4 in 2%.

Neutropenia was reported as a serious adverse reaction in <1% of patients and <1% of patients discontinued due to neutropenia. The incidence of neutropenia was higher in patients with multiple myeloma (16%) compared to patients with mantle cell lymphoma (5%). The incidence of ≥Grade 3 neutropenia also was higher in patients with multiple myeloma (12%) compared to patients with mantle cell lymphoma (3%).

Asthenic Conditions (Fatigue, Malaise, Weakness, Asthenia) Asthenic conditions were reported in 54% of patients. Fatigue was reported as Grade 3 in 7% and ≥Grade 4 in <1% of patients. Asthenia was reported as Grade 3 in 2% and ≥Grade 4 in <1% of patients. Two percent (2%) of patients discontinued treatment due to fatigue and <1% due to weakness and asthenia.

Asthenic conditions were reported in 53% of patients with multiple myeloma and 59% of patients with mantle cell lymphoma. Pyrexia Pyrexia (>38°C) was reported as an adverse reaction for 21% of patients. The reaction was Grade 3 in 1% and ≥Grade 4 in <1%. Pyrexia was reported as a serious adverse reaction in 3% of patients and led to VELCADE discontinuation in <1% of patients.

The incidence of pyrexia was higher among patients with multiple myeloma (23%) compared to patients with mantle cell lymphoma (10%). The incidence of ≥Grade 3 pyrexia was 1% in patients with multiple myeloma and <1% in patients with mantle cell lymphoma. Herpes Virus Infection Consider using antiviral prophylaxis in subjects being treated with VELCADE.

In the randomized studies in previously untreated and relapsed multiple myeloma, herpes zoster reactivation was more common in subjects treated with VELCADE (ranging between 6 to 11%) than in the control groups (3 to 4%). Herpes simplex was seen in 1 to 3% in subjects treated with VELCADE and 1 to 3% in the control groups.

In the previously untreated multiple myeloma study, herpes zoster virus reactivation in the VELCADE, melphalan and prednisone arm was less common in subjects receiving prophylactic antiviral therapy (3%) than in subjects who did not receive prophylactic antiviral therapy (17%). Retreatment in Relapsed Multiple Myeloma A single-arm trial was conducted in 130 patients with relapsed multiple myeloma to determine the efficacy and safety of retreatment with intravenous VELCADE.

The safety profile of patients in this trial is consistent with the known safety profile of VELCADE-treated patients with relapsed multiple myeloma as demonstrated in Tables 10, 11, and 13; no cumulative toxicities were observed upon retreatment. The most common adverse drug reaction was thrombocytopenia which occurred in 52% of the patients.

The incidence of ≥Grade 3 thrombocytopenia was 24%. Peripheral neuropathy occurred in 28% of patients, with the incidence of ≥Grade 3 peripheral neuropathy reported at 6%. The incidence of serious adverse reactions was 12.3%. The most commonly reported serious adverse reactions were thrombocytopenia (3.8%), diarrhea (2.3%), and herpes zoster and pneumonia (1.5% each).

Adverse reactions leading to discontinuation occurred in 13% of patients. The reasons for discontinuation included peripheral neuropathy (5%) and diarrhea (3%). Two deaths considered to be VELCADE-related occurred within 30 days of the last VELCADE dose; one in a patient with cerebrovascular accident and one in a patient with sepsis.

Additional Adverse Reactions from Clinical Studies The following clinically important serious adverse reactions that are not described above have been reported in clinical trials in patients treated with VELCADE administered as monotherapy or in combination with other chemotherapeutics. These studies were conducted in patients with hematological malignancies and in solid tumors.

Blood and Lymphatic System Disorders: Anemia, disseminated intravascular coagulation, febrile neutropenia, lymphopenia, leukopenia Cardiac Disorders: Angina pectoris, atrial fibrillation aggravated, atrial flutter, bradycardia, sinus arrest, cardiac amyloidosis, complete atrioventricular block, myocardial ischemia, myocardial infarction, pericarditis, pericardial effusion, Torsades de pointes, ventricular tachycardia Ear and Labyrinth Disorders: Hearing impaired, vertigo Eye Disorders: Diplopia and blurred vision, conjunctival infection, irritation Gastrointestinal Disorders: Abdominal pain, ascites, dysphagia, fecal impaction, gastroenteritis, gastritis hemorrhagic, hematemesis, hemorrhagic duodenitis, ileus paralytic, large intestinal obstruction, paralytic intestinal obstruction, peritonitis, small intestinal obstruction, large intestinal perforation, stomatitis, melena, pancreatitis acute, oral mucosal petechiae, gastroesophageal reflux General Disorders and Administration Site Conditions: Chills, edema, edema peripheral, injection site erythema, neuralgia, injection site pain, irritation, malaise, phlebitis Hepatobiliary Disorders: Cholestasis, hepatic hemorrhage, hyperbilirubinemia, portal vein thrombosis, hepatitis, liver failure Immune System Disorders: Anaphylactic reaction, drug hypersensitivity, immune complex mediated hypersensitivity, angioedema, laryngeal edema Infections and Infestations: Aspergillosis, bacteremia, bronchitis, urinary tract infection, herpes viral infection, listeriosis, nasopharyngitis, pneumonia, respiratory tract infection, septic shock, toxoplasmosis, oral candidiasis, sinusitis, catheter-related infection Injury, Poisoning and Procedural Complications: Catheter-related complication, skeletal fracture, subdural hematoma Investigations: Weight decreased Metabolism and Nutrition Disorders: Dehydration, hypocalcemia, hyperuricemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia Musculoskeletal and Connective Tissue Disorders: Arthralgia, back pain, bone pain, myalgia, pain in extremity Nervous System Disorders: Ataxia, coma, dizziness, dysarthria, dysesthesia, dysautonomia, encephalopathy, cranial palsy, grand mal convulsion, headache, hemorrhagic stroke, motor dysfunction, neuralgia, spinal cord compression, paralysis, postherpetic neuralgia, transient ischemic attack Psychiatric Disorders: Agitation, anxiety, confusion, insomnia, mental status change, psychotic disorder, suicidal ideation Renal and Urinary Disorders: Calculus renal, bilateral hydronephrosis, bladder spasm, hematuria, hemorrhagic cystitis, urinary incontinence, urinary retention, renal failure (acute and chronic), glomerular nephritis proliferative Respiratory, Thoracic and Mediastinal Disorders: Acute respiratory distress syndrome, aspiration pneumonia, atelectasis, chronic obstructive airways disease exacerbated, cough, dysphagia, dyspnea, dyspnea exertional, epistaxis, hemoptysis, hypoxia, lung infiltration, pleural effusion, pneumonitis, respiratory distress, pulmonary hypertension Skin and Subcutaneous Tissue Disorders: Urticaria, face edema, rash (which may be pruritic), leukocytoclastic vasculitis, pruritus Vascular Disorders: Cerebrovascular accident, cerebral hemorrhage, deep venous thrombosis, hypertension, peripheral embolism, pulmonary embolism, pulmonary hypertension

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified from the worldwide postmarketing experience with VELCADE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Cardiac Disorders: Cardiac tamponade Ear and Labyrinth Disorders: Deafness bilateral Eye Disorders: Optic neuropathy, blindness, chalazion/blepharitis Gastrointestinal Disorders: Ischemic colitis Infections and Infestations: Progressive multifocal leukoencephalopathy (PML), ophthalmic herpes, herpes meningoencephalitis Nervous System Disorders: Posterior reversible encephalopathy syndrome (PRES, formerly RPLS), Guillain-Barré syndrome, demyelinating polyneuropathy Respiratory, Thoracic and Mediastinal Disorders: Acute diffuse infiltrative pulmonary disease Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute febrile neutrophilic dermatosis (Sweet's syndrome)

Adverse reaction frequency tables (US label) US FDA label
Table 9: Most Commonly Reported Adverse Reactions (≥10% in the VELCADE, Melphalan and Prednisone Arm) with Grades 3 and ≥4 Intensity in the Previously Untreated Multiple Myeloma Study
VELCADE, Melphalan and PrednisoneMelphalan and Prednisone
(n=340)(n=337)
Body SystemTotalToxicity Grade, n (%)TotalToxicity Grade, n (%)
Adverse Reactionn (%)3≥4n (%)3≥4
Blood and Lymphatic System Disorders
Thrombocytopenia164 (48)60 (18)57 (17)140 (42)48 (14)39 (12)
Neutropenia160 (47)101 (30)33 (10)143 (42)77 (23)42 (12)
Anemia109 (32)41 (12)4 (1)156 (46)61 (18)18 (5)
Leukopenia108 (32)64 (19)8 (2)93 (28)53 (16)11 (3)
Lymphopenia78 (23)46 (14)17 (5)51 (15)26 (8)7 (2)
Gastrointestinal Disorders
Nausea134 (39)10 (3)070 (21)1 (<1)0
Diarrhea119 (35)19 (6)2 (1)20 (6)1 (<1)0
Vomiting87 (26)13 (4)041 (12)2 (1)0
Constipation77 (23)2 (1)014 (4)00
Abdominal pain upper34 (10)1 (<1)020 (6)00
Nervous System Disorders
Peripheral neuropathyRepresents High Level Term Peripheral Neuropathies NEC156 (46)42 (12)2 (1)4 (1)00
Neuralgia117 (34)27 (8)2 (1)1 (<1)00
Paresthesia42 (12)6 (2)04 (1)00
General Disorders and Administration Site Conditions
Fatigue85 (25)19 (6)2 (1)48 (14)4 (1)0
Asthenia54 (16)18 (5)023 (7)3 (1)0
Pyrexia53 (16)4 (1)019 (6)1 (<1)1 (<1)
Infections and Infestations
Herpes Zoster39 (11)11 (3)09 (3)4 (1)0
Metabolism and Nutrition Disorders
Anorexia64 (19)6 (2)019 (6)00
Skin and Subcutaneous Tissue Disorders
Rash38 (11)2 (1)07 (2)00
Psychiatric Disorders
Insomnia35 (10)1 (<1)021 (6)00
Table 10: Most Commonly Reported Adverse Reactions (≥10% in VELCADE Arm), with Grades 3 and 4 Intensity in the Relapsed Multiple Myeloma Study of VELCADE vs Dexamethasone (N=663)
VELCADE (N=331)Dexamethasone (N=332)
Adverse ReactionsAllGrade 3Grade 4AllGrade 3Grade 4
Any Adverse Reactions324 (98)193 (58)28 (8)297 (89)110 (33)29 (9)
Nausea172 (52)8 (2)031 (9)00
Diarrhea NOS171 (52)22 (7)036 (11)2 (<1)0
Fatigue130 (39)15 (5)082 (25)8 (2)0
Peripheral neuropathiesRepresents High Level Term Peripheral Neuropathies NEC115 (35)23 (7)2 (<1)14 (4)01 (<1)
Thrombocytopenia109 (33)80 (24)12 (4)11 (3)5 (2)1 (<1)
Constipation99 (30)6 (2)027 (8)1 (<1)0
Vomiting NOS96 (29)8 (2)010 (3)1 (<1)0
Anorexia68 (21)8 (2)08 (2)1 (<1)0
Pyrexia66 (20)2 (<1)021 (6)3 (<1)1 (<1)
Paresthesia64 (19)5 (2)024 (7)00
Anemia NOS63 (19)20 (6)1 (<1)21 (6)8 (2)0
Headache NOS62 (19)3 (<1)023 (7)1 (<1)0
Neutropenia58 (18)37 (11)8 (2)1 (<1)1 (<1)0
Rash NOS43 (13)3 (<1)07 (2)00
Appetite decreased NOS36 (11)0012 (4)00
Dyspnea NOS35 (11)11 (3)1 (<1)37 (11)7 (2)1 (<1)
Abdominal pain NOS35 (11)5 (2)07 (2)00
Weakness34 (10)10 (3)028 (8)8 (2)0
Table 11: Most Commonly Reported Adverse Reactions (≥10%), with Grade 3 and ≥4 Intensity in the Relapsed Multiple Myeloma Study (N=221) of VELCADE Subcutaneous vs Intravenous
SubcutaneousIntravenous
(N=147)(N=74)
Body SystemTotalToxicity Grade, n (%)TotalToxicity Grade, n (%)
Adverse Reactionn (%)3≥4n (%)3≥4
Note: Safety population: 147 patients in the subcutaneous treatment group and 74 patients in the intravenous treatment group who received at least one dose of study medication
Blood and Lymphatic System Disorders
Anemia28 (19)8 (5)017 (23)3 (4)0
Leukopenia26 (18)8 (5)015 (20)4 (5)1 (1)
Neutropenia34 (23)15 (10)4 (3)20 (27)10 (14)3 (4)
Thrombocytopenia44 (30)7 (5)5 (3)25 (34)7 (9)5 (7)
Gastrointestinal Disorders
Diarrhea28 (19)1 (1)021 (28)3 (4)0
Nausea24 (16)0010 (14)00
Vomiting13 (9)3 (2)08 (11)00
General Disorders and Administration Site Conditions
Asthenia10 (7)1 (1)012 (16)4 (5)0
Fatigue11 (7)3 (2)011 (15)3 (4)0
Pyrexia18 (12)006 (8)00
Nervous System Disorders
Neuralgia34 (23)5 (3)017 (23)7 (9)0
Peripheral neuropathiesRepresents High Level Term Peripheral Neuropathies NEC55 (37)8 (5)1 (1)37 (50)10 (14)1 (1)
Table 12: Most Commonly Reported Adverse Reactions (≥5%) with Grades 3 and ≥4 Intensity in the Previously Untreated Mantle Cell Lymphoma Study
VcR-CAP (n=240)R-CHOP (n=242)
Body System Adverse ReactionsAll n (%)Toxicity Grade 3 n (%)Toxicity Grade ≥4 n (%)All n (%)Toxicity Grade 3 n (%)Toxicity Grade ≥4 n (%)
Key: R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; VcR-CAP = VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone.
Blood and Lymphatic System Disorders
Neutropenia209 (87)32 (13)168 (70)172 (71)31 (13)125 (52)
Leukopenia116 (48)34 (14)69 (29)87 (36)39 (16)27 (11)
Anemia106 (44)27 (11)4 (2)71 (29)23 (10)4 (2)
Thrombocytopenia172 (72)59 (25)76 (32)42 (17)9 (4)3 (1)
Febrile neutropenia41 (17)24 (10)12 (5)33 (14)17 (7)15 (6)
Lymphopenia68 (28)25 (10)36 (15)28 (12)15 (6)2 (1)
Nervous System Disorders
Peripheral neuropathyRepresents High Level Term Peripheral Neuropathies NEC71 (30)17 (7)1 (<1)65 (27)10 (4)0
Hypoesthesia14 (6)3 (1)013 (5)00
Paresthesia14 (6)2 (1)011 (5)00
Neuralgia25 (10)9 (4)01 (<1)00
General Disorders and Administration Site Conditions
Fatigue43 (18)11 (5)1 (<1)38 (16)5 (2)0
Pyrexia48 (20)7 (3)023 (10)5 (2)0
Asthenia29 (12)4 (2)1 (<1)18 (7)1 (<1)0
Edema peripheral16 (7)1 (<1)013 (5)00
Gastrointestinal Disorders
Nausea54 (23)1 (<1)028 (12)00
Constipation42 (18)1 (<1)022 (9)2 (1)0
Stomatitis20 (8)2 (1)019 (8)01 (<1)
Diarrhea59 (25)11 (5)011 (5)3 (1)1 (<1)
Vomiting24 (10)1 (<1)08 (3)00
Abdominal distension13 (5)004 (2)00
Infections and Infestations
Pneumonia20 (8)8 (3)5 (2)11 (5)5 (2)3 (1)
Skin and Subcutaneous Tissue Disorders
Alopecia31 (13)1 (<1)1 (<1)33 (14)4 (2)0
Metabolism and Nutrition Disorders
Hyperglycemia10 (4)1 (<1)017 (7)10 (4)0
Decreased appetite36 (15)2 (1)015 (6)1 (<1)0
Vascular Disorders
Hypertension15 (6)1 (<1)03 (1)00
Psychiatric Disorders
Insomnia16 (7)1 (<1)08 (3)00
Table 13: Most Commonly Reported (≥10% Overall) Adverse Reactions in Integrated Analyses of Relapsed Multiple Myeloma and Relapsed Mantle Cell Lymphoma Studies Using the 1.3 mg/m2 Dose (N=1163)
All Patients (N=1163)Multiple Myeloma (N=1008)Mantle Cell Lymphoma (N=155)
Adverse ReactionsAll≥Grade 3All≥Grade 3All≥Grade 3
Nausea567 (49)36 (3)511 (51)32 (3)56 (36)4 (3)
Diarrhea NOS530 (46)83 (7)470 (47)72 (7)60 (39)11 (7)
Fatigue477 (41)86 (7)396 (39)71 (7)81 (52)15 (10)
Peripheral neuropathiesRepresents High Level Term Peripheral Neuropathies NEC443 (38)129 (11)359 (36)110 (11)84 (54)19 (12)
Thrombocytopenia369 (32)295 (25)344 (34)283 (28)25 (16)12 (8)
Vomiting NOS321 (28)44 (4)286 (28)40 (4)35 (23)4 (3)
Constipation296 (25)17 (1)244 (24)14 (1)52 (34)3 (2)
Pyrexia249 (21)16 (1)233 (23)15 (1)16 (10)1 (<1)
Anorexia227 (20)19 (2)205 (20)16 (2)22 (14)3 (2)
Anemia NOS209 (18)65 (6)190 (19)63 (6)19 (12)2 (1)
Headache NOS175 (15)8 (<1)160 (16)8 (<1)15 (10)0
Neutropenia172 (15)121 (10)164 (16)117 (12)8 (5)4 (3)
Rash NOS156 (13)8 (<1)120 (12)4 (<1)36 (23)4 (3)
Paresthesia147 (13)9 (<1)136 (13)8 (<1)11 (7)1 (<1)
Dizziness (excl vertigo)129 (11)13 (1)101 (10)9 (<1)28 (18)4 (3)
Weakness124 (11)31 (3)106 (11)28 (3)18 (12)3 (2)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Based on its mechanism of action [see Clinical Pharmacology (12.1)] and findings in animals, VELCADE can cause fetal harm when administered to a pregnant woman. There are no studies with the use of VELCADE in pregnant women to inform drug-associated risks. Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see Data).

Advise pregnant women of the potential risk to the fetus. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data Animal Data Bortezomib was not teratogenic in nonclinical developmental toxicity studies in rats and rabbits at the highest dose tested (0.075 mg/kg; 0.5 mg/m 2 in the rat and 0.05 mg/kg; 0.6 mg/m 2 in the rabbit) when administered during organogenesis. These dosages are approximately 0.5 times the clinical dose of 1.3 mg/m 2 based on body surface area.

Bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (approximately 0.5 times the clinical dose of 1.3 mg/m 2 based on body surface area). Pregnant rabbits given bortezomib during organogenesis at a dose of 0.05 mg/kg (0.6 mg/m 2) experienced significant postimplantation loss and decreased number of live fetuses.

Live fetuses from these litters also showed significant decreases in fetal weight.

Mechanism of action

12.1 Mechanism of Action Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells.

Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models, including multiple myeloma.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Following twice weekly administration of 1 mg/m 2 and 1.3 mg/m 2 bortezomib doses, the maximum inhibition of 20S proteasome activity (relative to baseline) in whole blood was observed five minutes after drug administration. Comparable maximum inhibition of 20S proteasome activity was observed between 1 and 1.3 mg/m 2 doses. Maximal inhibition ranged from 70% to 84% and from 73% to 83% for the 1 mg/m 2 and 1.3 mg/m 2 dose regimens, respectively.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose.

Excretion The pathways of elimination of bortezomib have not been characterized in humans.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Following intravenous administration of 1 mg/m 2 and 1.3 mg/m 2 doses, the mean maximum plasma concentrations of bortezomib (C max) after the first dose (Day 1) were 57 and 112 ng/mL, respectively. When administered twice weekly, the mean maximum observed plasma concentrations ranged from 67 to 106 ng/mL for the 1 mg/m 2 dose and 89 to 120 ng/mL for the 1.3 mg/m 2 dose.

Following an intravenous bolus or subcutaneous injection of a 1.3 mg/m 2 dose to patients with multiple myeloma, the total systemic exposure after repeat dose administration (AUC last) was equivalent for subcutaneous and intravenous administration. The AUC last geometric mean ratio (90% confidence interval) was 0.99 (0.80 to 1.23).

The C max after subcutaneous administration (20.4 ng/mL) was lower than after intravenous administration (223 ng/mL) with repeat dose administration. Distribution The mean distribution volume of bortezomib ranged from approximately 498 to 1884 L/m 2 following single- or repeat-dose administration of 1 mg/m 2 or 1.3 mg/m 2 to patients with multiple myeloma.

The binding of bortezomib to human plasma proteins averaged 83% over the concentration range of 100 to 1000 ng/mL. Elimination The mean elimination half-life of bortezomib upon multiple dosing ranged from 40 to 193 hours after the 1 mg/m 2 dose and 76 to 108 hours after the 1.3 mg/m 2 dose. The mean total body clearances were 102 and 112 L/h following the first dose for doses of 1 mg/m 2 and 1.3 mg/m 2, respectively, and ranged from 15 to 32 L/h following subsequent doses for doses of 1 and 1.3 mg/m 2, respectively.

Metabolism Bortezomib is primarily oxidatively metabolized to several inactive metabolites in vitro via cytochrome P450 (CYP) enzymes 3A4, CYP2C19, and CYP1A2, and to a lesser extent by CYP2D6 and CYP2C9. Excretion The pathways of elimination of bortezomib have not been characterized in humans. Specific Populations No clinically significant differences in the pharmacokinetics of bortezomib were observed based on age, sex, or renal impairment (including patients administered VELCADE after dialysis).

The effect of race on bortezomib pharmacokinetics is unknown. Patients with Hepatic Impairment Following administration of bortezomib doses ranging from 0.5 to 1.3 mg/m 2, mild (total bilirubin ≤1× ULN and AST >ULN, or total bilirubin >1 to 1.5× ULN and any AST) hepatic impairment did not alter dose-normalized bortezomib AUC when compared to patients with normal hepatic function.

Dose normalized mean bortezomib AUC increased by approximately 60% in patients with moderate (total bilirubin >1.5 to 3× ULN and any AST) or severe (total bilirubin >3× ULN and any AST) hepatic impairment. A lower starting dose is recommended in patients with moderate or severe hepatic impairment. Drug Interaction Studies Clinical Studies No clinically significant differences in bortezomib pharmacokinetics were observed when coadministered with dexamethasone (weak CYP3A4 inducer), omeprazole (strong CYP2C19 inhibitor), or melphalan in combination with prednisone.

Strong CYP3A4 Inhibitor Coadministration with ketoconazole (strong CYP3A4 inhibitor) increased bortezomib exposure by 35%. Strong CYP3A4 Inducer Coadministration with rifampin (strong CYP3A4 inducer) decreased bortezomib exposure by approximately 45%. In Vitro Studies Bortezomib may inhibit CYP2C19 activity and increase exposure to drugs that are substrates for this enzyme.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. VELCADE · Takeda Pharmaceuticals America, Inc. [US FDA-approved label, version 36, August 28, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .